 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
23 News |  |
- Lu AF20513 / Lundbeck, Otsuka
Trial primary completion date: Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD (clinicaltrials.gov) - Feb 23, 2020
P1, N=3, Terminated, Sponsor: H. Lundbeck A/S
Trial primary completion date: Mar 2019 --> Jun 2019
- Lu AF20513 / Lundbeck, Otsuka
Trial primary completion date: Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Nov 29, 2019
P1, N=50, Terminated, Sponsor: H. Lundbeck A/S
Trial primary completion date: Mar 2019 --> Jun 2019 Trial primary completion date: Jan 2019 --> Jul 2019
- Lu AF20513 / Lundbeck, Otsuka
Trial primary completion date: A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD) (clinicaltrials.gov) - Nov 20, 2019
P1, N=18, Terminated, Sponsor: H. Lundbeck A/S
Trial primary completion date: Jan 2019 --> Jul 2019 Trial primary completion date: Feb 2019 --> May 2019
- | Lu AF20513 / Lundbeck, Otsuka
Trial completion date, Trial termination, Trial primary completion date: Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Jul 17, 2019
P1, N=50, Terminated, Sponsor: H. Lundbeck A/S
Trial primary completion date: Feb 2019 --> May 2019 Trial completion date: Dec 2019 --> Jul 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Jan 2019; New data: The study was terminated based on new efficacy data from another study
- | Lu AF20513 / Lundbeck, Otsuka
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD (clinicaltrials.gov) - Jul 16, 2019
P1, N=3, Terminated, Sponsor: H. Lundbeck A/S
Trial completion date: Dec 2019 --> Jul 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Jan 2019; New data: The study was terminated based on new efficacy data from another study N=28 --> 3 | Trial completion date: Dec 2019 --> Jun 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Mar 2019; New data: The study was terminated based on new efficacy data from another study
- ||| Lu AF20513 / Lundbeck, Otsuka
Trial termination: A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD) (clinicaltrials.gov) - Jun 11, 2019
P1, N=18, Terminated, Sponsor: H. Lundbeck A/S
N=28 --> 3 | Trial completion date: Dec 2019 --> Jun 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Mar 2019; New data: The study was terminated based on new efficacy data from another study Active, not recruiting --> Terminated; New data: The study was terminated based on new efficacy data from another study
- || Lu AF20513 / Lundbeck, Otsuka
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD) (clinicaltrials.gov) - May 7, 2019
P1, N=18, Active, not recruiting, Sponsor: H. Lundbeck A/S
Active, not recruiting --> Terminated; New data: The study was terminated based on new efficacy data from another study Enrolling by invitation --> Active, not recruiting | N=57 --> 18 | Trial completion date: Feb 2022 --> May 2019 | Trial primary completion date: Feb 2022 --> May 2019
- || Lu AF20513 / Lundbeck, Otsuka
Enrollment closed: Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD (clinicaltrials.gov) - May 7, 2019
P1, N=28, Active, not recruiting, Sponsor: H. Lundbeck A/S
Enrolling by invitation --> Active, not recruiting | N=57 --> 18 | Trial completion date: Feb 2022 --> May 2019 | Trial primary completion date: Feb 2022 --> May 2019 Recruiting --> Active, not recruiting
- | Lu AF20513 / Lundbeck, Otsuka
Trial completion date, Trial primary completion date: Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD (clinicaltrials.gov) - Feb 24, 2019
P1, N=28, Recruiting, Sponsor: H. Lundbeck A/S
Recruiting --> Active, not recruiting Trial completion date: Jun 2019 --> Jan 2020 | Trial primary completion date: Apr 2019 --> Jan 2020
- || Lu AF20513 / Lundbeck, Otsuka
Trial completion date, Trial primary completion date: A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD) (clinicaltrials.gov) - Feb 15, 2019
P1, N=57, Enrolling by invitation, Sponsor: H. Lundbeck A/S
Trial completion date: Jun 2019 --> Jan 2020 | Trial primary completion date: Apr 2019 --> Jan 2020 Trial completion date: Nov 2020 --> Feb 2022 | Trial primary completion date: Nov 2020 --> Feb 2022
- || Lu AF20513 / Lundbeck, Otsuka
New P1 trial: Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD (clinicaltrials.gov) - Jan 28, 2019
P1, N=28, Recruiting, Sponsor: H. Lundbeck A/S
- | Lu AF20513 / Lundbeck, Otsuka
New P1 trial: A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD) (clinicaltrials.gov) - Sep 12, 2018
P1, N=57, Enrolling by invitation, Sponsor: H. Lundbeck A/S
- || Lu AF20513 / Lundbeck, Otsuka
Enrollment closed: Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - May 30, 2018
P1, N=50, Active, not recruiting, Sponsor: H. Lundbeck A/S
Trial completion date: Nov 2020 --> Feb 2022 | Trial primary completion date: Nov 2020 --> Feb 2022 Recruiting --> Active, not recruiting
- Lu AF20513 / Lundbeck, Otsuka
Enrollment open: Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Apr 20, 2018
P1, N=50, Recruiting, Sponsor: H. Lundbeck A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- Lu AF20513 / Lundbeck, Otsuka
Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Apr 19, 2018
P1, N=50, Active, not recruiting, Sponsor: H. Lundbeck A/S
Active, not recruiting --> Recruiting Trial completion date: Dec 2020 --> Dec 2019 | Trial primary completion date: Dec 2020 --> Oct 2019
- Lu AF20513 / Lundbeck, Otsuka
Enrollment change, Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Mar 21, 2018
P1, N=50, Active, not recruiting, Sponsor: H. Lundbeck A/S
Trial completion date: Dec 2020 --> Dec 2019 | Trial primary completion date: Dec 2020 --> Oct 2019 N=35 --> 50 | Trial completion date: Oct 2018 --> Dec 2020 | Trial primary completion date: Oct 2018 --> Dec 2020
- Lu AF20513 / Lundbeck, Otsuka
Enrollment closed, Trial primary completion date: Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Mar 16, 2017
P1, N=35, Active, not recruiting, Sponsor: H. Lundbeck A/S
N=35 --> 50 | Trial completion date: Oct 2018 --> Dec 2020 | Trial primary completion date: Oct 2018 --> Dec 2020 Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Oct 2018
- Lu AF20513 / Lundbeck, Otsuka
Trial primary completion date: Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Sep 29, 2015
P1, N=35, Recruiting, Sponsor: H. Lundbeck A/S
Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Oct 2018 Trial primary completion date: Dec 2016 --> May 2017
- | Lu AF20513 / Lundbeck, Otsuka
New P1 trial: Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Mar 14, 2015
P1, N=35, Recruiting, Sponsor: H. Lundbeck A/S